2021
DOI: 10.3389/fimmu.2021.707734
|View full text |Cite
|
Sign up to set email alerts
|

Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies

Abstract: Transcription factor and oncosuppressor protein p53 is considered as one of the most promising molecular targets that remains a high-hanging fruit in cancer therapy. TP53 gene encoding the p53 protein is known to be the most frequently mutated gene in human cancers. The loss of transcriptional functions caused by mutations in p53 protein leads to deactivation of intrinsic tumor suppressive responses associated with wild-type (WT) p53 and acquisition of new pro-oncogenic properties such as enhanced cell prolife… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
30
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 35 publications
(33 citation statements)
references
References 67 publications
0
30
0
Order By: Relevance
“…In our study, greater GGH expression was associated with higher clinical stage, higher histological grade, and mixed histological type. In addition, GGH expression was significantly higher in UCEC patients receiving minimally invasive surgery, those carrying the TP53 mutation, black or African-American patients, and patients with BMI ≤30 or weight ≤80 kg, all of which are associated with lower survival rates in other cancers ( Palumbo et al, 2002 ; Melamed et al, 2018 ; Donehower et al, 2019 ; Chasov et al, 2021 ).…”
Section: Discussionmentioning
confidence: 99%
“…In our study, greater GGH expression was associated with higher clinical stage, higher histological grade, and mixed histological type. In addition, GGH expression was significantly higher in UCEC patients receiving minimally invasive surgery, those carrying the TP53 mutation, black or African-American patients, and patients with BMI ≤30 or weight ≤80 kg, all of which are associated with lower survival rates in other cancers ( Palumbo et al, 2002 ; Melamed et al, 2018 ; Donehower et al, 2019 ; Chasov et al, 2021 ).…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, the remaining 95% of CRCs often exhibit a lower tumor mutation burden, limiting the efficacy of immunotherapies based on conventional T cells that recognize mutated epitopes. Current efforts address the targeting of common genetic alterations such as TP53 mutations, which are found in 70% of COAD [ 33 ], by humoral and cell-based immunotherapies, including T cell receptor mimic monoclonal antibodies [ 34 ]. Our data suggest that patients with an infiltration of α-GalCer-producing bacteria in the tumor tissues could benefit from immunotherapy based on non-conventional T cells.…”
Section: Discussionmentioning
confidence: 99%
“…The use of additional checkpoint inhibitors such as TIM-3 may also overcome T-cell exhaustion and rescue AML that is resistant to initial PD1/PD-L1 blockade [ 86 ]. Immune therapies have the potential to overcome chemotherapy-resistant forms of AML, including those with P53 mutations [ 144 ]. A variety of novel immune-modulating mAbs, engineered mAb constructs, ADC, and cellular and vaccine therapies have emerged as promising therapies for patients with R/R MDS and AML, with new therapeutic strategies being identified at an exponential pace.…”
Section: Discussionmentioning
confidence: 99%